Litcius/Paper detail

LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

Benjamin Besse, Jessica Menis, Paolo Bironzo, R. Gervais, Laurent Greillier, I. Monnet, Lorenzo Livi, Robyn R. Young, C. Decroisette, Nicolas Cloarec, G. Robinet, Roland Schött, Raffaele Califano, Filippo de Marinis, Giuseppe Luigi Banna, Murielle Mauer, Alessia Pochesci, Baktiar Hasan, Thierry Berghmans, Anne‐Marie C. Dingemans

2020Annals of Oncology25 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicinePembrolizumabClinical endpointEtoposideHazard ratioCarboplatinGastroenterologyPopulationLung cancerRandomizationPhases of clinical researchSurgeryChemotherapyCancerRandomized controlled trialConfidence intervalImmunotherapyCisplatinEnvironmental healthLung Cancer Research StudiesPeptidase Inhibition and AnalysisNeuroendocrine Tumor Research Advances
LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer | Litcius